Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 401–500 of 991
Jiang, H., & Zhang, Q. (2024) · Oncology Letters · doi:10.3892/ol.2024.14221 · Cited by 36
“Another clinical trial evaluating ipilimumab for the treatment of metastatic melanoma found an inverse association between the increase of specific bacteria in the Bacteroidetes phylum and colitis after immunotherapy (98).”
BackgroundCheckpoint inhibitor colitis: a new model of inflammatory bowel disease?
Siakavellas, S. I., & Bamias, G. (2018) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000482 · Cited by 36
Emerging role of microbiota in immunomodulation and cancer immunotherapy
Singh, R. P., Bashir, H., & Kumar, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.008 · Cited by 35
Immunotherapy Use in Patients With Lung Cancer and Comorbidities
von Itzstein, M. S., Gonugunta, A. S., Mayo, H., Minna, J. D., & Gerber, D. E. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000484 · Cited by 33
Luo, B., Zhang, Y., Zhang, C., Liu, X., & Shi, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.001 · Cited by 34
The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
Rahman, R. A., Lamarca, Á., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2021) · Cancers · doi:10.3390/cancers13153779 · Cited by 36
Galloway-Peña, J., Jenq, R. R., & Shelburne, S. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3173 · Cited by 37
“Finally, the abundance of the Bacteroidetes phylum was recently correlated with resistance to the development of immune-mediated colitis in melanoma patients treated with the immune check-point inhibitor, ipilimumab [31].”
BackgroundDrug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis
Sayers, E., MacGregor, A. J., & Carding, S. R. (2018) · AIMS Microbiology · doi:10.3934/microbiol.2018.4.642 · Cited by 36
“The higher abundance of members from the phylum Bacteroidetes was also associated with protection from anti-CTLA-4-induced colitis, further confirming the benefits that these bacteria could have in anti-CTLA-4 antibody therapy [24].”
BackgroundMicrobiota modification in hematology: still at the bench or ready for the bedside?
Severyn, C. J., Brewster, R., & Andermann, T. M. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000365 · Cited by 34
“In addition, the relative abundance of gut microbes prior to ICI treatment has been correlated with ICI-related toxicity within the gut.(15,16) Notably, vancomycin-induced severe colitis in mice administered anti–CTLA-4 antibody therapy was ameliorated by the administration of a mixture of Bifidobacterium species, sug…”
BackgroundMicrobiome and host crosstalk: A new paradigm to cancer therapy
Singh, A. K., Nayak, N., Rathi, P., Verma, D., Sharma, R., Chaudhary, A., Agarwal, A., Tripathi, Y. B., & Garg, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.014 · Cited by 35
Bayless, N. L., Bluestone, J. A., Bucktrout, S. L., Butterfield, L. H., Jaffee, E. M., Koch, C. A., Roep, B. O., Sharpe, A. H., Murphy, W. J., Villani, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002627 · Cited by 33
Burcher, K. M., Burcher, J. T., Inscore, L., Bloomer, C. H., Furdui, C. M., & Porosnicu, M. (2022) · Cancers · doi:10.3390/cancers14174116 · Cited by 37
Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
Zhou, G., Zhang, N., Meng, K., & Pan, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001623 · Cited by 39
“(17) the USA MM (n=34) Not available Anti-CTLA-4 (n=34) Fecal Colitis (n=10) Bacteroidetes phylum and three of its families (Bacteroidaceae, Rikenellaceae, Barnesiellaceae) had higher abundance in colitisfree patient.”
BackgroundThe Gut Microbiota in Causation, Detection, and Treatment of Cancer
Murphy, C. L., O’Toole, P. W., & Shanahan, F. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000075 · Cited by 36
Tucci, M., Passarelli, A. M., Todisco, A., Mannavola, F., Stucci, L. S., D’Oronzo, S., Rossini, M., Taurisano, M., Gesualdo, L., & Silvestris, F. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875549 · Cited by 34
Dougan, M. L. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-0752-z · Cited by 36
Emerging roles of the gut microbiota in cancer immunotherapy
Shi, Z., Li, H., Song, W., Zhou, Z., Li, Z., & Zhang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139821 · Cited by 34
“Furthermore, the pre-inflammation fecal microbiota of melanoma patients that presented a paucity of genetic pathways related to polyamine transport and B vitamin biosynthesis was linked with an increased risk of colitis (55).”
BackgroundAchilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Yan, T., Yu, L., Zhang, J., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292122 · Cited by 44
“Notably, individuals with higher levels of Bacteroides fragilis are found to have a reduced risk of colitis, while those with an abundance of Firmicutes face an increased risk (30, 31).”
BackgroundGut Microbiome–Colorectal Cancer Relationship
Yadav, D., Sainatham, C., Filippov, E., Kanagala, S. G., Ishaq, S. M., & Jayakrishnan, T. (2024) · Microorganisms · doi:10.3390/microorganisms12030484 · Cited by 40
“The microbiome could also help to predict immunotherapy-related toxicity based on findings correlating bacterial species and the development of checkpoint-blockade-induced colitis [108].”
BackgroundCirculating microbiome DNA: An emerging paradigm for cancer liquid biopsy
Chen, H., Ma, Y., Liu, Z., Li, J., Li, X., Yang, F., & Qiu, M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.036 · Cited by 34
Liu, Y., Zhang, Z., Wang, S., Fu, S., Cheng, X., Chen, R., & Sun, T. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108900 · Cited by 35
Gut microbiota shed new light on the management of immune‐related adverse events
Tan, B., Liu, Y., Tang, H. T., Chen, D., Xu, Y., Chen, M., Li, Y., Wang, M., & Qian, J. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14626 · Cited by 36
Microbiota-targeted therapies in inflammation resolution
Strati, F., Lattanzi, G., Amoroso, C., & Facciotti, F. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101599 · Cited by 33
Microbiota as the unifying factor behind the hallmarks of cancer
Benešová, I., Křížová, Ľ., & Kverka, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05244-6 · Cited by 35
“…phylum renders malignant melanoma patients more resistant to ipilimumab-induced colitis, whereas the microbiota enriched in Faecalibacterium spp., and other Firmicutes is associated with more frequent colitis but also longer progression-free survival (Chaput et al. 2017; Dubin et al. 2016).”
BackgroundGut microbiome and immune checkpoint inhibitor toxicity
Verheijden, R. J., van Eijs, M. J. M., Paganelli, F. L., Viveen, M. C., Rogers, M. R. C., Top, J., May, A. M., van de Wijgert, J. H. H. M., & Suijkerbuijk, K. P. M. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115221 · Cited by 37
Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers
Zhang, X., & Pan, Z. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa014 · Cited by 32
The Microbiome and Its Implications in Cancer Immunotherapy
Choudhry, H. (2021) · Molecules · doi:10.3390/molecules26010206 · Cited by 31
Kong, X., Lü, P., Liu, C., Guo, Y., Yang, Y., Peng, Y., Wang, F., Zhang, B., Dou, X., Shi, H., et al. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12001 · Cited by 30
“By contrast, the intestinal harmful bacteria (Bacteroidales) weakened antigen presentation and impaired anti‐tumor immune response (118,119).”
BackgroundYura, Y., & Hamada, M. (2022) · Cancers · doi:10.3390/cancers14030792 · Cited by 35
“[76] found that species belonging to the Bacteroidetes phylum conferred resistance to colitis that developed after anti-CTLA-4 antibody therapy, suggesting that expansion of these bacteria helps to prevent the development of ICI-induced colitis.”
BackgroundRole of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
Wang, D., Gu, Y., Yan, X., Huo, C.-D., Wang, G., Zhao, Y., Teng, M., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844260 · Cited by 41
Liu, X., Tang, H. T., Zhou, Q., Zeng, Y., Lu, B., Chen, D., Li, Y., Qian, J., Chen, M., Zhao, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1109281 · Cited by 35
“However, the b-diversity, which measures microbial composition heterogeneity between samples, was higher in patients who developed irAEs compared with those who did not, consistent with previous studies (11, 15).”
BackgroundResultSex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses
Canzian, J., Conforti, F., Jacobs, F., Benvenuti, C., Gaudio, M., Gerosa, R., Sanctis, R. D., & Zambelli, A. (2025) · Cancers · doi:10.3390/cancers17071054 · Cited by 35
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics
Araujo, D. V., Watson, G. A., Oliva, M., Heirali, A., Coburn, B., Spreafico, A., & Siu, L. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102125 · Cited by 29
Egami, S., Kawazoe, H., Hashimoto, H., Uozumi, R., Arami, T., Sakiyama, N., Ohe, Y., Nakada, H., Aomori, T., Ikemura, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.618570 · Cited by 32
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 31
“The use of anti‐CTLA4 antibody in cancer patients is often associated with dysbiosis and with inflammatory colitis as irAEs (124).”
BackgroundInfluentialGiommoni, E., Giorgione, R., Paderi, A., Pellegrini, E., Gambale, E., Marini, A., Antonuzzo, A., Marconcini, R., Roviello, G., Matucci‐Cerinic, M., et al. (2021) · Immuno · doi:10.3390/immuno1030017 · Cited by 33
“Other predictive biomarkers of toxicity investigated include subpopulations of lymphocytes [18–20], various cytokines, such as interleukin (IL) 6 and 17 [19,21,22], C-reactive protein (CRP) [23,24], multiple chemokines [25], autoantibodies [26–31], single-nucleotide polymorphisms (SNPs) [32,33], microRNA [34], the mic…”
BackgroundThompson, N., Stewart, G. D., Welsh, S. J., Doherty, G. J., Robinson, M. J., Neville, B. A., Vervier, K., Harris, S. R., Adams, D. J., Dalchau, K. M., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09156-x · Cited by 32
Strategies for Predicting Response to Checkpoint Inhibitors
Zappasodi, R., Wolchok, J. D., & Merghoub, T. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0471-9 · Cited by 30
Self-citationMiao, J., Sise, M. E., & Herrmann, S. M. (2022) · Frontiers in Nephrology · doi:10.3389/fneph.2022.1017921 · Cited by 34
Sasson, S. C., Zaunders, J., Nahar, K. J., Munier, C. M. L., Fairfax, B. P., Olsson-Brown, A. C., Jolly, C., Read, S. A., Ahlenstiel, G., Palendira, U., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13502 · Cited by 27
Zheng, M., Mao, P., Tian, X., & Meng, L. (2020) · Poultry Science · doi:10.1016/j.psj.2020.11.005 · Cited by 29
“Faecalibacterium, an SCFA-producing bacteria, can induce the expansion of T-regulatory cells or stimulate the production of anti-inflammatory cytokines (Dubin et al., 2016).”
BackgroundPortenkirchner, C., Kienle, P., & Horisberger, K. (2021) · Pharmaceuticals · doi:10.3390/ph14040367 · Cited by 30
“Furthermore, different intestinal microbiomes have been found to be associated with improvement or alternatively with the risk of developing ICI-induced colitis [29,100,101].”
BackgroundYou, L., Zhou, J., Xin, Z., Hauck, J. S., Na, F., Tang, J., Zhou, X., Lei, Z., & Ying, B. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac005 · Cited by 35
Checkpoint Inhibitor-Induced Colitis: An Update
Losurdo, G., Angelillo, D., Favia, N., Sergi, M. C., Leo, A. D., Triggiano, G., & Tucci, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051496 · Cited by 30
“Furthermore, a prospective study on colitis in patients treated with ipilimumab for melanoma discovered that patients resistant to ICI-induced colitis had higher concentrations of Bacteroidetes bacteria, underlining the function of microbial factors [18].”
BackgroundCheckpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
Terrin, M., Migliorisi, G., Buono, A. D., Gabbiadini, R., Mastrorocco, E., Quadarella, A., Repici, A., Santoro, A., & Armuzzi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411504 · Cited by 34
“Similarly, Bifidobacterium is reported to be associated with a lower risk of CIC, while Clostridia and Escherichia may carry a higher risk [88,89].”
BackgroundHwang, S. W., Kim, M. K., & Kweon, M. (2023) · Intestinal Research · doi:10.5217/ir.2023.00019 · Cited by 29
“Dubin et al.(58) investigated baseline microbiota from metastatic melanoma patients prior to anti-CTLA-4 treatment and showed that a higher abundance of Bacteroidetes phylum and 3 of its families (Bacteroidaceae, Rikenellaceae, and Barnesiellaceae) was correlated with resistance to ICI-induced colitis.”
BackgroundKähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 28
Neurologic Toxicities of Cancer Immunotherapies: a Review
Harrison, R. A., Tummala, S., & de Groot, J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01038-2 · Cited by 28
Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies
Rinninella, E., Raoul, P. C., Cintoni, M., Palombaro, M., Pulcini, G., Gasbarrini, A., & Mele, M. C. (2021) · Microorganisms · doi:10.3390/microorganisms9071469 · Cited by 28
“Specifically, this phylum was associated with a lower risk of developing colitis in melanoma patients treated with anti-CTLA-4 therapy [43].”
BackgroundLongitudinal Characterization of the Gut Bacterial and Fungal Communities in Yaks
Wang, Y., Fu, Y., He, Y., Kulyar, M. F., Iqbal, M., Li, K., & Liu, J. (2021) · Journal of Fungi · doi:10.3390/jof7070559 · Cited by 28
“Rikenellaceae was associated with limiting inflammation in the host [45], and this process was achieved by stimulating T-cell regulatory differentiation.”
BackgroundDelire, B., Martin, E. D., Meunier, L., Larrey, D. G., & Horsmans, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786174 · Cited by 30
Chen, M.-M., Liu, M., Li, C., Peng, S., Li, Y., Xu, X., Sun, M., & Sun, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.913217 · Cited by 30
Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 29
Dingenen, L. V., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar‐Singh, S., Malhotra‐Kumar, S., & Houdt, R. V. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1298264 · Cited by 31
Gut Microbiota Secondary Metabolites: Key Roles in GI Tract Cancers and Infectious Diseases
Anwer, E. K. E., Ajagbe, M., Sherif, M. A., Musaibah, A. S., Mahmoud, S., ElBanbi, A., & Abdelnaser, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010100 · Cited by 36
Tini, S., Baima, J., Pigni, S., Antoniotti, V., Caputo, M., Palma, E. D., Cerbone, L., Grosso, F., Vecchia, M. L., Bona, E., et al. (2025) · Nutrients · doi:10.3390/nu17172898 · Cited by 30
Patil, P. D., Burotto, M., & Velcheti, V. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1440209 · Cited by 28
“higher representation of Bacteroidetes phylum are associated with resistance to CTLA-4 blockade induced colitis [64,65].”
BackgroundCancer and immunotherapy: a role for microbiota composition
Pham, F., Moinard‐Butot, F., Coutzac, C., & Chaput, N. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.051 · Cited by 29
Bardoscia, L., Pasinetti, N., Triggiani, L., Cozzi, S., & Sardaro, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.746853 · Cited by 30
Knisely, A. T., Seo, Y. D., Wargo, J. A., & Chelvanambi, M. (2023) · Cancers · doi:10.3390/cancers15030777 · Cited by 32
“Subsequent work in a prospective group of melanoma patients treated with ipilimumab demonstrated increased representation of the Bacteroidetes phylum correlating with resistance to immunemediated colitis, further supporting the hypothesis generated by the preclinical work [96].”
ResultImmune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
O’Leary, C. L., Pierce, N., Patel, S. P., & Naidoo, J. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.11.018 · Cited by 34
Bruneau, A., Baylatry, M., Joly, A. C., & Sokol, H. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.10.025 · Cited by 35
Abu‐Sbeih, H., & Wang, Y. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz212 · Cited by 27
The Interplay between Tumour Microenvironment Components in Malignant Melanoma
Amălinei, C., Grigoraş, A., Lozneanu, L., Căruntu, I.-D., Giuşcă, S. E., & Balan, R. A. (2022) · Medicina · doi:10.3390/medicina58030365 · Cited by 30
“Additionally, it has been demonstrated that patients containing Bacteroidaceae, Barnesiellaceae, and Rikenellaceae in their microbiota do not show colitis induced by anti-CTLA-4 therapy [278].”
BackgroundThe intricate connection between diet, microbiota, and cancer: A jigsaw puzzle
Arkan, M. C. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.009 · Cited by 32
Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications
Güven, D. C., Aktaş, B. Y., Şimşek, C., & Aksoy, S. (2020) · Future Oncology · doi:10.2217/fon-2019-0783 · Cited by 26
Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy
Anfossi, S., & Călin, G. A. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.04 · Cited by 35
“Increased representation of members of the Bacteroidetes phylum (Bacteroidaceae, Rikenellaceae and Barnesiellaceae families) inhibit the development of colitis induced by anti-CTLA-4 immunotherapy and this is associated with the biosynthesis of B vitamins[87].”
BackgroundKubo, T., Hirohashi, Y., Tsukahara, T., Kanaseki, T., Murata, K., Morita, R., & Torigoe, T. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1976942 · Cited by 26
“associated with ICI induced colitis [84,85].”
Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
Zhou, Y., Liu, Z., & Chen, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847350 · Cited by 32
“Considering that anti-CTLA-4-treated melanoma patients rich in Bacteroidetes harness a lower risk for colitis mediated by the Tregs differentiation process, efforts to explore whether the anti-PD1/ PD-L1 related toxicity could also be ameliorated in a bacteriadependent manner are currently on the way (68).”
BackgroundGarczyk, A., Kaliciak, I., Drogowski, K., Horwat, P., Kopeć, S., Staręga, Z., Bogdański, P., Stelmach-Mardas, M., & Mardas, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123412 · Cited by 30
“Furthermore, the polyamine transport deficiencies associated with the increased risk of cytotoxic T cell antigen 4 (CTLA-4) blockade-induced colitis may be caused by this disruption to the ecological network balance in the gastrointestinal tract [44].”
BackgroundYang, S., Zhao, S., Ye, Y., Jia, L., & Lou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952546 · Cited by 32
“cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) (26), PD-1 (31, 32) and PD-L1 (25) were closely related to GM; the GM can predict clinical response and adverse effects in cancer patients treated with ICIs (27, 29, 30); antibiotics can alter the GM and affect the clinical efficacy of ICIs (33); specific gut bacter…”
BackgroundImplication of gut microbes and its metabolites in colorectal cancer
Kumar, A., Ali, A., Kapardar, R. K., Dar, G. M., Nimisha, Apurva, A., Sharma, A. K., Verma, R., Sattar, R. S. A., Ahmad, E., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04422-2 · Cited by 26
Challenges and exploration for immunotherapies targeting cold colorectal cancer
Li, D., Tang, Y., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i1.55 · Cited by 30
The Microbiota: A New Variable Impacting Cancer Treatment Outcomes
Fessler, J. L., & Gajewski, T. F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0864 · Cited by 24
“In melanoma patients treated with ipilimumab, a positive association was identified between resistance to immune-mediated colitis and bacteria belonging to the Bacteroidetes phylum (7).”
BackgroundImmune-mediated colitis after immune checkpoint inhibitor therapy
Giesler, S., Riemer, R., Lowinus, T., & Zeiser, R. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.09.009 · Cited by 29
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Carbonnel, F., Soularue, É., Coutzac, C., Chaput, N., Mateus, C., Lepage, P., & Robert, C. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-016-0613-x · Cited by 28
Chattopadhyay, I., Nandi, D., & Nag, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.012 · Cited by 27
Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy
Dougan, M. L. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0372 · Cited by 26
“Consistent with this hypothesis, contents of the pretreatment microbiome modify risk for colitis from checkpoint blockade, and fecal microbiota transplant has been successful in treating a small number of patients with refractory disease (32, 33).”
BackgroundImmunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword
Ballman, M., Zhao, C. N., McAdams, M. J., & Rajan, A. (2022) · Cancers · doi:10.3390/cancers14092060 · Cited by 31
“Studies in patients with melanoma have demonstrated that baseline microbiota compositions with a higher representation of bacteria belonging to the Bacteroidetes phylum are associated with resistance to the development of CTLA-4-induced colitis [88,89].”
BackgroundImmune-Related Adverse Events of the Gastrointestinal System
Nicolaides, S., & Boussioutas, A. (2023) · Cancers · doi:10.3390/cancers15030691 · Cited by 28
“These results are consistent with findings in other studies characterizing protective factors for the development of ICI colitis [20].”
BackgroundResultYan, J., Chen, T., Li, L., Liu, F., Liu, X., & Li, L. (2023) · Food & Function · doi:10.1039/d3fo01451g · Cited by 27
How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?
Mendes, I., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411855 · Cited by 24
“Even though there is substantial data for particular gut microbial characteristics linked to positive responses in mouse investigations [215,228], occurs a major disagreement on which microbiome features are related to therapy reactions in the human setting (Table 1).”
BackgroundPark, J. S., Gazzaniga, F. S., Kasper, D. L., & Sharpe, A. H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01075-0 · Cited by 25
“The Bacteroidetes phylum is more prevalent in melanoma patients who are resistant to the development of anti-CTLA-4-associated colitis 150 , and metagenomic analyses in this study revealed an association of vitamin B biosynthesis pathways and polyamine transport with resistance to colitis…”
Innao, V., Allegra, A. G., Musolino, C., & Allegra, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238902 · Cited by 37
“reduced ipilimumab-induced colitis and diarrhea [57], probably due to accumulation and maturation of plasmacytoid dendritic cells in mesenteric lymph nodes, finally responsible for stimulating Treg-cell proliferation in the lamina propria [64].”
BackgroundImmune Checkpoint Inhibitors and Cardiovascular Adverse Events
Perna, M. L. D., Rigamonti, E., Zannoni, R., Espeli, V. G., & Moschovitis, G. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15281 · Cited by 28
Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
Eiman, L., Moazzam, K., Anjum, S., Kausar, H., Sharif, E. A. M., & Ibrahim, W. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575452 · Cited by 32
Gut microbiome-based medical methodologies for early-stage disease prevention
Wang, J.-Z., Du, W.-T., Xu, Y., Cheng, S.-Z., & Liu, Z. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.02.024 · Cited by 26
The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments
Son, Y. M., & Kim, J. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2208.08002 · Cited by 26
“Some gut microbial taxa, including bacteria belonging to the Bacteroidetes phylum, are found to be protective against immunotherapy toxicity and are more frequently present in patients that are resistant to ipilimumab-induced colitis [155].”
BackgroundFrąk, M., Grenda, A., Krawczyk, P. A., Milanowski, J., & Kalinka‐Warzocha, E. (2022) · Cancers · doi:10.3390/cancers14225577 · Cited by 28
Acute Kidney Injury in Cancer Immunotherapy Recipients
Joseph, A., Lafarge, A., Azoulay, É., & Zafrani, L. (2022) · Cells · doi:10.3390/cells11243991 · Cited by 24
“The proportion of patients affected by irAEs depends on the therapeutic target, tumor type [52] and recipient characteristics, such as younger age [53], microbiota composition [54] and history of autoimmune disease [55,56].”
BackgroundWang, Y., Xia, X., Zhou, X., Zhan, T., Dai, Q., Zhang, Y., Zhang, W., Shu, Y., Li, W., & Xu, H. Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1114586 · Cited by 23
Constantin, M., Chifiriuc, M. C., Mihăescu, G., Corcionivoschi, N., Burlibaşa, L., Bleoţu, C., Tudorache, S. I., Mitache, M. M., Filip, R., Munteanu, S.-G., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1373504 · Cited by 27
“Several studies have identi fi ed Bacteroidetes as a biomarker indicating non-responsiveness to immune checkpoint inhibitors in patients with metastatic melanoma (MM) (101, 102).”
BackgroundAntibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature
Lopes, M. S. M., Machado, L. M., Silva, P. A. I. A., Uchiyama, A. A. T., Yen, C. T., Ricardo, E. D., Mutão, T. S., Pimento, J. R., Shimba, D. S., Hanriot, R. D. M., et al. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1106 · Cited by 28
“Bacteroidetes phylum, for example, appears to have a protective effect against checkpoint inhibitor-induced colitis [30].”
BackgroundKoulouridi, A., Messaritakis, I., Gouvas, N., Tsiaoussis, J., & Souglakos, J. (2020) · Cancers · doi:10.3390/cancers13010043 · Cited by 27
“4% of melanoma patients under anti-CTLA-4, and their gut microbiota was mainly composed of microorganisms belonging to the phylum of Bacteroidetes, families of Bacteroidaceae, Rikenellaceae and Barnesiellaceae [11].”
BackgroundInfluentialHe, Z., Xie, H., Xu, H., Wu, J., Zeng, W., He, Q., Jobin, C., Jin, S., & Lan, P. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2319511 · Cited by 27
“25,26 Infiltration of tumor-specific T cells by anti-PD-L1 was also mediated by the enrichment of Bifidobacterium .”
BackgroundClinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 33
Wardill, H. R., & Tissing, W. J. E. (2017) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000265 · Cited by 25
Cassol, C. A., Owen, D. H., Kendra, K. L., Braga, J. R., Frankel, W. L., & Arnold, C. A. (2020) · Histopathology · doi:10.1111/his.14115 · Cited by 22
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
Pilla, L., Alberti, A., di Mauro, P., Gemelli, M. T., Cogliati, V., Cazzaniga, M. E., Bidoli, P., & Maccalli, C. (2020) · Cancers · doi:10.3390/cancers12113456 · Cited by 31
“found that in 34 patients treated with Ipilimumab, the presence of species from the Bacteroidetes phylum was associated with decreased risk of ICI-induced colitis [75].”
BackgroundAjgal, Z. C., Goulvestre, C., Zaibet, S., Arrondeau, J., Bretagne, M., Peyromaure, M., Batteux, F., Alexandre, J., Goldwasser, F., & Huillard, O. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.04.002 · Cited by 23
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.